Table 1 Patient characteristics (n = 30)
  Characteristic | No. of patients | % patients |
|---|---|---|
Age (years) | ||
  Median (range) | 65 (42–81) | |
Gender | ||
  Male | 16 | 53 |
  Female | 14 | 47 |
Karnofsky performance status | ||
  90-100 | 22 | 73 |
  70-80 | 8 | 27 |
  0-60 | 0 | 0 |
Tumor location | ||
  Head | 15 | 50 |
  Body and Tail | 15 | 50 |
Nodal status | ||
  Negative | 18 | 60 |
  Positive | 12 | 40 |
Baseline tumor diameter (cm) | ||
  Median (range) | 4.5 (2.1-7.8) | |
Baseline serum CA19-9 level (U/ml) | ||
  Median (range) | 872 (0–35490) | |
  ≥ 1,000 | 14 | 47 |
  100-1,000 | 11 | 37 |
  < 100 | 5 | 17 |
Pre-CRT tumor diameter (cm) | ||
  Median (Range) | 4.1 (1.9-8.4) | |
Pre-CRT serum CA19-9 Level (U/ml) | ||
  Median | 631 (0–50440) | |
  ≥ 1,000 | 11 | 37 |
  100-1,000 | 12 | 40 |
  < 100 | 7 | 23 |
Regimens of primary chemotherapy | ||
  Gemcitabine alone | 24 | 80 |
  Gemcitabine + α | 6 | 20 |